A Young Researcher Advocates for Strong Federal Funding

Scientific advancements are made through scientific research. From understanding the basic biology behind a disease to testing how well a drug targets a disease, the majority of this research is funded by the National Institutes of Health (NIH). So, on September 14, 2017, hundreds of people from 37 states and Washington, D.C., from over 300 institutes and organizations, gathered for the 5th Annual Rally for Medical Research with a common message

Read More

Q&A with Anil K. Sood, MD, on Ovarian Cancer Research and Treatment

On Sunday, almost 300 of the greatest minds in ovarian cancer research will come together in Pittsburgh to discuss the latest advances in the field at the American Association for Cancer Research four-day conference on Addressing Critical Questions in Ovarian Cancer Research and Treatment.

Read More

Cultivating a More Diverse Scientific Work Force

The U.S. Latino population surged 243 percent from 1980 to 2010. But in the same time span, the Latino physician work force dropped from 135 to 105 physicians per 100,000, according to a study by the Center for the Study of Latino Health and Culture at the University of California, Los Angeles.

This decline is alarming. It means that the growing Latino population does not get culturally competent care needed to improve patient health outcomes.

Read More

How Mouse Models Pave the Way to Precision Cancer Medicine

The AACR is holding a special conference, Advances in Modeling Cancer in Mice: Technology, Biology, and Beyond, in Orlando, Florida, September 24-27. This conference will highlight recent advances in the design and implementation of genetically engineered mouse models of cancer.

Read More

AACR Cancer Progress Report 2017: Harnessing Research Discoveries to Save Lives

Today, the American Association for Cancer Research (AACR) released its seventh annual Cancer Progress Report. The report highlights how federally funded research that provides a deep understanding of the biology of cancer is spurring advances across the clinical cancer care continuum that are improving survival and quality of life for people around the world.

Read More

New Treatment for Adults with Acute Lymphoblastic Leukemia Approved by the FDA

This week’s excitement surrounding the groundbreaking U.S. Food and Drug Administration (FDA) approval of the CAR T–cell therapy tisagenlecleucel (Kymriah) for treating certain pediatric and young adult patients with acute lymphoblastic leukemia (ALL) was not the only good news for ALL community in August. Earlier in the month, the FDA approved a new molecularly targeted therapeutic called inotuzumab ozogamicin (Besponsa) for treating adults who have B-cell precursor ALL that did not respond to initial treatment or that returned after treatment.

Read More

Lessons Learned From Combining Anti-OX40 and Anti-PD1 Immunotherapies

A pair of studies published recently in journals of the American Association for Cancer Research bring to our attention the unexpected negative consequences of combining two immunotherapeutics concurrently, and discuss the mechanisms behind improved antitumor effects and survival outcomes with sequential administration of the two drugs.

Read More

FDA Approves Two New Treatments for Acute Myeloid Leukemia

This week, the U.S. Food and Drug Administration (FDA) added two new treatments to the armamentarium for hematologic oncologists treating certain groups of patients with acute myeloid leukemia (AML): enasidenib (Idhifa) and Vyxeos. This news is particularly welcome because AML is the form of leukemia with the lowest five-year relative survival rate.

Read More